ABSTRACT:Many people who have suffering from heart problems or strokes which caused by blood clots, to help reduce their risk of further heart problems or strokes. Yosprala, a new chemical entity Approved by USFDA in Sept 2016 to treat Mini stroke, Ischemic Heart disease, Peptic ulcer. The Active ingredients present are Aspirin (325 mg) and Omeprazole (40 mg). Aspirin is Antiplatelet agent and Omeprazole is proton pump inhibitor. Therefore it is made to develop a new Analytical method for Simultaneous estimation of Aspirin and Omeprazole using Mehtanol as solvent on basis of solubility. The maximum Absorption (? max) of Aspirin and Omeprazole was at 276 and 301 respectively. Linearity range for aspirin was 10-50µg/ml with %RSD value 0.997 and Omeprazole was 2-10µg/ml with %RSD value 0.997. The method was validated for precision and % RSD was less than 2.0 for both aspirin and omeprazole. The proposed method was statistically validated for standard deviation, relative standard deviation, coefficient of variance and the results were within the range. Hence the above method was simple, cheap, cost effective, economical, and robust.